Catalyst Wire Dossier Catalyst Wire Dossier

Roflumilast Foam 0.3%

roflumilast
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Roflumilast Foam 0.3%, covering 2025-08-08 to 2025-08-08. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV) [Phase 2]

See pricing